Matinas Biopharma Holdings Inc Stock News

In the last trading session, 1.18 million shares of the Matinas BioPharma Holdings Inc. (AMEX:MTNB) were traded, and its beta was 2.18. Most recently the companys share price was $1.05, and it changed around -$0.02 or -1.87% from the last close, which brings the market valuation of the company to $229.20M. MTNB currently trades at Matinas BioPharma Holdings Inc. (AMEX: MTNB): The Stock To Bet On For Economic Progress In The Months Ahead Read More »

Vanguard Group Inc. grew its holdings in Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) by 0.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,872,463 shares of the companys stock after purchasing an additional 20,613 shares during the quarter. Vanguard Group Inc. owned []

BEDMINSTER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, has been invited to present a Company overview at the Piper Sandler 33 rd Annual Virtual Healthcare Conference, being held November 29 December 2, 2021. The Company will also host investor meetings during the conference.

Penny stocks to buy right now according to analysts. The post 5 Penny Stocks To Buy According To Analysts With Targets Up To 156% appeared first on Penny Stocks to Buy, Picks, News and Information | P

Penny stocks to buy right now according to analysts. The post 5 Penny Stocks To Buy According To Analysts With Targets Up To 156% appeared first on Penny Stocks to Buy, Picks, News and Information | P

Matinas BioPharma Holdings, Inc.'s (MTNB) CEO Jerome Jabbour on Q3 2021 Results - Earnings Call Transcript

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead

These penny stocks exploded during today's trading session, are they worth watching or not? The post 5 Penny Stocks to Watch That Exploded Today, What You Need to Know appeared first on Penny Stocks t

BEDMINSTER, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, presented a Company overview a

Matinas BioPharma Holdings Inc (NYSE: MTNB) has announced positive data from the first two cohorts of the Phase 2 EnACT trial of MAT2203 (oral amphotericin B) for cryptococcal meningitis. The study

– Step-down therapy with MAT2203 achieved effective clearance of fungal organisms; Mean Early Fungicidal Activity (EFA) was 0.38, exceeding the prespecified primary endpoint threshold target of >0.2

Method-of-use patent strengthens and diversifies MAT2203's long-term patent portfolio Method-of-use patent strengthens and diversifies MAT2203's long-term patent portfolio

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerome Jabbour on Q2 2021 Results - Earnings Call Transcript

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for

– Enrollment complete in second cohort of EnACT study of MAT2203 (oral amphotericin B) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) review of safety and efficacy data from sec